A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
研究单位：[1]Eisai Inc. ( Eisai Limited )[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]Beijing Anding Hospital Beijing,Beijing,China[4]The First Affiliated Hospital of Chongqing Medical University Chongqing,Chongqing,China[5]The Second Affiliated Hospital of Chongqing Medical University Chongqing,Chongqing,China[6]Guangzhou First People's Hospital Guangzhou,Guangdong,China[7]The People's Hospital of Guangxi Zhuang Autonomous Region Nanning,Guangxi,China[8]Tongji Hospital,Tongji Medical College of HUST Wuhan,Hubei,China[9]The Third Xiangya Hospital of Central South University Changsha,Hunan,China[10]Union Hospital,Tongji Medical college Huazhong University of Science and Technology Wuhan,Hubei,China
研究目的：
The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.
